Q2 2020 Kindred Biosciences Inc Earnings Call
At this time, all participants have been placed on a listen only mode.
The end of the prepared statements participants will have the opportunity to ask questions.
Please note that the remarks today will include forward looking statements and that actual results could differ materially from those projected or implied in our forward looking statements.
Brad description of important factors that could cause actual results to differ.
We refer you to the forward looking statements in today's press release.
And the note on forward looking statements in the Companys STC filings.
It is now my pleasure to turn the call over to Kindred bio CEO Richard chain Dr. Chan. Please proceed.
Thank you operator, good afternoon, and welcome to our second quarter Twentytwenty financial results call.
Joining me today from the management team up Kindred bio our Wendy Lee, our CFO and catch up here.
VP of corporate development and Investor Relations.
Before I start out with that thank our co founder third the need for her incredible contribution.
To kindred bio.
Beneath has been instrumental and growing kindred bio into one of the world's leading veterinary biopharmaceutical company.
And I look forward to our ongoing collaboration on the board as we continue to real life. Our vision for this pioneering company we've built together.
Thanks to our recent strategic decisions, we are strongly position for success.
Our focus is on our highest value program and with the Opex expected to drop to $10 million per quarter by Q4, we have the cash runway to see us through an important milestone and thereby realized the value of our late stage assets.
Turning to our pipeline, we're pleased with our progress in the second quarter.
Manufacturing for IL 31, antibody, which now has the you send name turn out that Matt has been going well and we continue to expect the pivotal study to start this year.
Manufacturing scale scale up is tracking to our expectation.
As you know atopic dermatitis is a very large attractive area. There are couple of approved product that in aggregate sell more than $800 million per year and theyre still growing.
But this is perspective.
$800 million.
He is a sizable well selling human product, but instead of a billion dollars to develop a drug we can do so far one 100.
That cost.
Now the currently marketed products are excellent drugs, but we think.